logo
Twitter
Discord
Email
logo
AVITA Medical, Inc.

AVITA Medical, Inc.

NASDAQ•RCEL
CEO: Mr. James M. Corbett
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2012-05-14
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Contact Information
28159 Avenue Stanford, Suite 220, Valencia, CA, 91355, United States
661-367-9170
www.avitamedical.com
Market Cap
$110.30M
P/E (TTM)
-2.6
33.6
Dividend Yield
--
52W High
$11.25
52W Low
$3.22
52W Range
15%
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$17.06M-12.71%
4-Quarter Trend

EPS

-$0.46-25.81%
4-Quarter Trend

FCF

-$6.17M-44.02%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine-Month Revenue Growth Total revenues reached $54.0M, increasing 18% for the nine months ended September 30, 2025.
Gross Profit Margin Improvement Gross profit $44.5M, increasing 14% for nine months, despite margin pressure from product mix.
Net Loss Significantly Reduced Net loss narrowed to $37.0M for nine months, representing a 26% reduction versus the prior year period.
Current Cash Position Cash and marketable securities totaled $23.3M as of September 30, 2025, supporting near-term operations.

Risk Factors

Cash Covenant Compliance Risk Management determined probable inability to maintain minimum cash balance covenant within next twelve months.
Credit Agreement Covenant Breaches Received waivers for Q1 and Q2 2025 trailing 12-month net revenue covenants; substantial doubt raised.
Macroeconomic Reimbursement Headwinds Changes in reimbursement rates could reduce demand for RECELL System, impacting revenue recovery efforts.

Outlook

Strategic Burn Center Focus Executing strategy targeting 200 U.S. burn and trauma centers to maximize portfolio adoption impact.
RECELL GO European Launch Obtained CE Mark for RECELL GO, enabling commercialization in EU, UK, and Australia markets.
Future Capital Requirements Actively evaluating strategies including equity financing or debt issuance to secure required additional funding.

Peer Comparison

Revenue (TTM)

Lucid Diagnostics Inc.LUCD
$1.21B
+28885.2%
Anika Therapeutics, Inc.ANIK
$112.81M
-31.3%
Owlet, Inc.OWLT
$99.66M
+26.8%

Gross Margin (Latest Quarter)

Sight Sciences, Inc.SGHT
86.4%
+2.5pp
AVITA Medical, Inc.RCEL
81.3%
-2.4pp
Apyx Medical CorporationAPYX
64.4%
+3.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
SGHT$318.29M-6.8-61.6%35.0%
OWLT$207.54M-5.3126.8%33.3%
RPID$182.61M-4.1-73.9%28.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.5%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 12, 2026
|
EPS:-$0.36
|
Revenue:$26.27M
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $17.06M-12.7%
    |
    EPS: $-0.46-25.8%
    Meet

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $18.42M+21.2%
    |
    EPS: $-0.38-36.7%
    Meet

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $18.51M+66.7%
    |
    EPS: $-0.53-27.4%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 13, 2025|
    Revenue: $64.25M+28.1%
    |
    EPS: $-2.39-70.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $19.55M-7.9%
    |
    EPS: $-0.62+17.0%
    Beat

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $15.20M-13.9%
    |
    EPS: $-0.60-3.2%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 13, 2024|
    Revenue: $11.10M+5.3%
    |
    EPS: $-0.73+32.7%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 22, 2024|
    Revenue: $50.14M+45.7%
    |
    EPS: $-1.40+10.8%
    Beat